|
Mutation Information
|
Mutation Site
|
T184S |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Genotype/Subtype
|
A |
|
Relevant Drug
|
lamivudine (LAM);entecavir (ETV) |
Literature Information
|
PubMed PMID
|
19301976
|
|
Disease
|
Chronic hepatitis B;
HBV-HIV coinfection
|
|
Published Year
|
2009 |
|
Journal
|
The Journal of infectious diseases |
|
Title
|
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. |
|
Author
|
Margeridon-Thermet S,Shulman NS,Ahmed A,Shahriar R,Liu T,Wang C,Holmes SP,Babrzadeh F,Gharizadeh B,Hanczaruk B,Simen BB,Egholm M,Shafer RW |
|
Evidence
|
UDPS detected drug-resistance mutations that were not detected by PCR in 10 samples from 5 NRTI-treated patients, including the lamivudine-resistance mutation V173L (in 5 samples), the entecavir-resistance mutations T184S (in 2 samples) and S202G (in 1 sample), the adefovir-resistance mutation N236T (in 1 sample), and the lamivudine and adefovir–resistance mutations V173L, L180M, A181T, and M204V (in 1 sample).
|
|
|
HBV Mutation Detail Information